BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that more mature interim TACTI-002 clinical data will be presented at the 34th German Cancer Congress taking place in Berlin from 19th to 22nd of February 2020.

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company donated RMB1 million worth of their most popular immune system boosting products to Shunchang General Hospital.

Next major milestone in Mino-Lok trial is the 75% interim analysis for superior efficacy and is expected in first half of 2020

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday, February 10, 2020, at 9:00 a.m. Eastern time.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that CEO Nadav Kidron will present a company overview at the BIO CEO & Investor Conference in New York City.

DILIsym Services Inc. (DSS), a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical efficacy and safety, today announced that it is developing a new component for a QSP model focused on treating heart failure, such as can occur after myocardial infarction.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today the launch of AiTraC 2020, the inaugural meeting on AI solutions for transplantation that will be held March 27-28, 2020 in South San Francisco, CA.

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound TTHX1114.

Samus Therapeutics, Inc. (“Samus” or the “Company”), a privately held, Boston-based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced the publication of preclinical research in the journal Nature Communications.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference, being held in New York City on February 10-11, 2020.